… lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today … The 2023 edition of the RNA Editing Summit will focus on optimizing RNA editing technology to safely deliver novel …
… addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,076,923 additional ordinary shares … the offering has been filed with the SEC. When available, copies of the final prospectus supplement and the … syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing …
… retinal disease, into the clinic and continuing the development of our portfolio of transformative RNA medicines … ProQR. “QR-421a has shown promising activity in both the optic cup and zebra fish models and we are excited about the … gene and will be conducted at expert sites in the US and Europe. It will be a double-masked, randomized study …
… Partnership focused on utilizing Axiomer ™ to develop editing oligonucleotides targeting an underlying … Collaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases … lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today …
… L’Agence européenne des médicaments accorde l’accès PRIME au … et seulement 20 % (une sur cinq) des demandes en ophtalmologie l'avaient été. « La décision de l’EMA … prometteuses de son programme principal en ACL10. À propos du Sepofarsen Le Sepofarsen est le premier …
… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa The trial, called WINGS, … with recessive dystrophic epidermolysis bullosa (RDEB) is open for enrollment. “The initiation of our first human … clinical trial for QR-313 is an exciting next step in the development of this novel investigational therapy for DEB. …